Cited by 146Cancer-related Molecular PathwaysGlioma Diagnosis and TreatmentChromatin Remodeling and Cancer

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma

Fulci, Giulia, Labuhn, Martin, Maier, Daniel, Lachat, Yan, Hausmann, Oliver, Hegi, Monika E, Janzer, Robert C, Merlo, Adrian, Van Meir, Erwin G·2000·Oncogene

DOI 10.1038/sj.onc.1203700

Open this paper in CoChat — free account

Abstract

P16 and P14ARF are two tumor suppressors encoded by the locus ink4a-arf which is frequently deleted in human tumors. Recent experiments performed with mouse embryonic fibroblasts have shown that P14ARF is an upstream regulator of the P53 pathway. This raises the question as to whether in human tumors the loss of p14arf and mutation of p53 are mutually exclusive events which segregate with genetic alterations at other loci. To examine this question we performed a multigenic analysis on 29 gliomas. We analysed p53 and p14arf in relation with five other genetic loci encoding the most frequently mutated genes in human gliomas: cdkn2a, mdm2, egfr, pten and the chromosomal regions 10q23.3 and 10q25-26. Our study shows for the first time that p53 mutations and p14arf deletions appear mutually exclusive in human glioblastoma, suggesting that they may be functionally redundant in glioma tumorigenesis. The P53 pathway is, therefore, disrupted in 81.8% of malignant gliomas (WHO grades III and IV), either by mutation of the p53 gene (31.8%) or by p14arf deletion (54.5%). These tumors further showed MDM2 overexpression (9.1%), egfr oncogene amplification/egfr overexpression (50%), pten mutations (27.3%) and loss of heterozygosity (LOH) at the chromosomal regions 10q23.3 (86.4%) and 10q25-26 (100%). These alterations did not segregate with p53 mutations or p14arf deletions, while p14arf and cdkn2a were always deleted.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1203700

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,474
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X.-D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
Kamb, A., Shattuck-Eidens, D. M., Eeles, R. A., Liu, Q., Gruis, N. A., Ding, W., Hussey, C. E., Tran, T., Miki, Y., Weaver-Feldhaus, J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-22 · Cited by 855
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
Cairns, P., Polascik, T. J., Eby, Y. J., Tokino, K., Califano, J. A., Merlo, A. U., Mao, L., Herath, J. F., Jenkins, R. B., Westra, W. H., et al. (1995) · Nature Genetics · doi:10.1038/ng1095-210 · Cited by 626
Self-citation
E1A signaling to p53 involves the p19ARFtumor suppressorPreprint
de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S.-Y., Ferbeyre, G., Samuelson, A. V., Prives, C. L., Roussel, M. F., Sherr, C. J., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.15.2434 · Cited by 611
Interaction between the retinoblastoma protein and the oncoprotein MDM2
Xiao, Z.-X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J. W., Sellers, W. R., & Livingston, D. M. (1995) · Nature · doi:10.1038/375694a0 · Cited by 586

Show all 41 references

Sorted by citations

Glioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 565
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Gliomagenesis: genetic alterations and mouse models
Holland, E. C. (2001) · Nature Reviews Genetics · doi:10.1038/35052535 · Cited by 461
The Molecular and Genetic Basis of Neurological Tumours
Zhu, Y. S., & Parada, L. F. (2002) · Nature reviews. Cancer · doi:10.1038/nrc866 · Cited by 325
Recent Advances in the Treatment of Malignant Astrocytoma
Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5302 · Cited by 309
Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
Uhrbom, L., Dai, C., Celestino, J., Rosenblum, M. K., Fuller, G. N., & Holland, E. C. (2002) · PubMed · Cited by 286
Deregulated Signaling Pathways in Glioblastoma Multiforme: Molecular Mechanisms and Therapeutic Targets
Mao, H., LeBrun, D. G., Yang, J., Zhu, V. F., & Li, M. (2012) · Cancer Investigation · doi:10.3109/07357907.2011.630050 · Cited by 277
Development of novel targeted therapies in the treatment of malignant glioma
Rich, J. N., & Bigner, D. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1380 · Cited by 250
NFKBIA Deletion in Glioblastomas
Bredel, M., Scholtens, D. M., Yadav, A. K., Alvarez, A. A., Renfrow, J. J., Chandler, J. P., Yu, I. L. Y., Carro, M. S., Dai, F., Tagge, M. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006312 · Cited by 247
EGFR overexpression and radiation response in glioblastoma multiforme
Barker, F. G., Simmons, M. L., Chang, S. M., Prados, M. D., Larson, D. A., Sneed, P. K., Wara, W. M., Berger, M. S., Chen, P., Israel, M. A., et al. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01609-1 · Cited by 243
Naturally occurring melanomas in dogs as models for non‐ UV pathways of human melanomas
Gillard, M., Cadieu, É., Brito, C. D., Abadie, J., Vergier, B., Devauchelle, P., Degorce‐Rubiales, F., Dréano, S., Primot, A., Dorso, L., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12170 · Cited by 174
Glioblastoma multiforme: a review of therapeutic targets
Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Bortoff, K., Bigner, D. D., Yan, H., & Adamson, D. C. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902942348 · Cited by 174
Glioblastoma Multiforme Oncogenomics and Signaling Pathways
Kanu, O. O., Hughes, B. D., Di, C., Lin, N., Fu, J., Bigner, D. D., Yan, H., & Adamson, C. (2009) · Clinical medicine Oncology · doi:10.4137/cmo.s1008 · Cited by 146
Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells.
Cobbs, C., Whisenhunt, T. R., Wesemann, D. R., Harkins, L. E., Meir, E. G. V., & Samanta, M. (2003) · PubMed · Cited by 144
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth
Landen, J. W., Hau, V. S., Wang, M., Davis, T. P., Ciliax, B. J., Wainer, B. H., Meir, E. G. V., Glass, J. D., Joshi, H. C., & Archer, D. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0360 · Cited by 130
INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas
Tannapfel, A., Busse, C., Weinans, L., Benicke, M., Katalinic, A., Geißler, F., Hauss, J., & Wittekind, C. (2001) · Oncogene · doi:10.1038/sj.onc.1204902 · Cited by 129
The Arf/p53 Pathway in Cancer and Aging
Matheu, A., Maraver, A., & Serrano, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6851 · Cited by 132
Distinct methylation profiles of glioma subtypes
Uhlmann, K., Rohde, K., Zeller, C., Szymaś, J., Vogel, S., Marczinek, K., Thiel, G., Nürnberg, P., & Laird, P. W. (2003) · International Journal of Cancer · doi:10.1002/ijc.11175 · Cited by 114
Genetic and epigenetic alterations as hallmarks of the intricate road to cancer
Macaluso, M., Paggi, M. G., & Giordano, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206955 · Cited by 112
Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas.
Chakravarti, A., Delaney, M. A., Noll, E., Black, P. M., Loeffler, J. S., Muzikansky, A., & Dyson, N. J. (2001) · PubMed · Cited by 111
The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero, A., Arcella, A., Gregorio, G. D., Porcellini, A., Mercola, D., Liu, C., Lombari, V., Zani, M., Giannini, G., Gagliardi, F., et al. (2001) · PubMed · Cited by 109
Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms
Silva, J., Silva, J. M., Domínguez, G., García, J. M., Cantos, B., Rodríguez, R., Larrondo, F. J., Provencio, M., España, P., & Bonilla, F. (2003) · The Journal of Pathology · doi:10.1002/path.1297 · Cited by 107
TP53 promoter methylation in human gliomas
Amatya, V. J., Naumann, U., Weller, M., & Ohgaki, H. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1041-5 · Cited by 102
Genetic and Biologic Progression in Astrocytomas and Their Relation to Angiogenic Dysregulation
Brat, D. J., Castellano-Sanchez, A. A., Kaur, B., & Meir, E. G. V. (2002) · Advances in Anatomic Pathology · doi:10.1097/00125480-200201000-00004 · Cited by 96
Oligodendroglial Tumors Frequently Demonstrate Hypermethylation of theCDKN2A(MTS1, p16INK4a),p14ARF, andCDKN2B(MTS2,p15INK4b) Tumor Suppressor Genes
Wolter, M., REIFENBERGER, J., Blaschke, B., Ichimura, K., Schmidt, E., Collins, V. P., & Reifenberger, G. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.12.1170 · Cited by 98
Neoplastic cells are a rare component in human glioblastoma microvasculature
Rodríguez, F. J., Orr, B. A., Ligon, K. L., & Eberhart, C. G. (2012) · Oncotarget · doi:10.18632/oncotarget.427 · Cited by 86
Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors
Domínguez, G., Silva, J., Garcia, J. M., Silva, J. M., Rodríguez, R., Muñoz, C., Chacón, I., Sanchez, R., Carballido, J., Colás, A., et al. (2003) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(03)00133-7 · Cited by 88
Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma
Calogero, A., Lombari, V., Gregorio, G. D., Porcellini, A., Ucci, S., Arcella, A., Caruso, R., Gagliardi, F. M., Gulino, A., Lanzetta, G., et al. (2004) · Cancer Cell International · doi:10.1186/1475-2867-4-1 · Cited by 85
Modulation of Cell Cycle Components by Epigenetic and Genetic Events
Macaluso, M., Montanari, M., Cinti, C., & Giordano, A. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.07.009 · Cited by 83
The INK4A/ARF Locus: Role in Cell Cycle Control and Apoptosis and Implications for Glioma Growth
Ivanchuk, S. M., Mondal, S., Dirks, P. B., & Rutka, J. T. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010632309113 · Cited by 81
Genetic modulation of hypoxia induced gene expression and angiogenesis relevance to brain tumors
Brat, D. J. (2003) · Frontiers in bioscience · doi:10.2741/942 · Cited by 78
Immunohistochemical Markers for Prognosis of Ependymal Neoplasms
Korshunov, A., Голанов, А. В., & Timirgaz, V. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1016222202230 · Cited by 75
Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma
Misra, A., Pellarin, M., Nigro, J. M., Smirnov, I. V., Moore, D. H., Lamborn, K. R., Pinkel, D., Albertson, D. G., & Feuerstein, B. G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0708 · Cited by 73
P14ARF inhibits human glioblastoma–induced angiogenesis by upregulating the expression of TIMP3
Zerrouqi, A., Pyrzynska, B., Febbraio, M., Brat, D. J., & Van Meir, E. G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci38596 · Cited by 70
The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma
Frank, A. J., Hernán, R., Hollander, A. B., Lindsey, J. C., Lusher, M. E., Fuller, C. E., Clifford, S. C., & Gilbertson, R. J. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.11.016 · Cited by 68
Genes and pathways driving glioblastomas in humans and murine disease models
Merlo, A. (2003) · Neurosurgical Review · doi:10.1007/s10143-003-0267-8 · Cited by 69
Self-citation
Quantitative real-time PCR does not show selective targeting of p14ARF but concomitant inactivation of both p16INK4A and p14ARF in 105 human primary gliomas
Labuhn, M., Jones, G., Speel, E. M., Maier, D., Zweifel, C., Gratzl, O., Meir, E. G. V., Hegi, M. E., & Merlo, A. U. (2001) · Oncogene · doi:10.1038/sj.onc.1204197 · Cited by 66
Self-citation
p14ARF nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways
Sánchez‐Aguilera, A., Sánchez‐Beato, M., García, J. F., Priéto, I., Pollán, M., & Piris, M. A. (2002) · Blood · doi:10.1182/blood.v99.4.1411 · Cited by 62
TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation
Puduvalli, V. K., Sampath, D., Bruner, J. M., Nangia, J. R., Xu, R., & Kyritsis, A. P. (2005) · APOPTOSIS · doi:10.1007/s10495-005-6078-3 · Cited by 60
A Review of the Molecular Mechanisms of Chemically Induced Neoplasia in Rat and Mouse Models in National Toxicology Program Bioassays and Their Relevance to Human Cancer
Hoenerhoff, M. J., Hong, H. H., Ton, T.-V., Lahousse, S. A., & Sills, R. C. (2009) · Toxicologic Pathology · doi:10.1177/0192623309351726 · Cited by 58
Structural mutation analysis of PTEN and its genotype‐phenotype correlations in endometriosis and cancer
Smith, I. N., & Briggs, J. M. (2016) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25105 · Cited by 55
Frequent LOH at Chromosome 12q22‐23 and Apaf‐1 Inactivation in Glioblastoma
Watanabe, T., Hirota, Y., Arakawa, Y., Fujisawa, H., Tachibana, O., Hasegawa, M., Yamashita, J., & Hayashi, Y. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00474.x · Cited by 55
Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma.
Nicholson, S. A., Okby, N. T., Ma, K., Welsh, J. A., McMenamin, M. G., Travis, W. D., Jett, J. R., Tazelaar, H. D., Trastek, V. F., Pairolero, P. C., et al. (2001) · PubMed · Cited by 53
Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr
Fedrigo, C. A., Grivicich, I., Schunemann, D. P., Chemale, I. M., dos Santos, D., Jacovas, T., Boschetti, P. S., Jotz, G. P., Filho, A. B., & da Rocha, A. B. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-156 · Cited by 52
Intratumoral Spread and Increased Efficacy of a p53-VP22 Fusion Protein Expressed by a Recombinant Adenovirus
Wills, K. N., Atencio, I. A., Avanzini, J. B., Neuteboom, S., Phelan, A., Philopena, J. M., Sutjipto, S., Vaillancourt, M. T., Wen, S. F., Ralston, R., et al. (2001) · Journal of Virology · doi:10.1128/jvi.75.18.8733-8741.2001 · Cited by 52
The status of gene therapy for brain tumors
Fulci, G., & Chiocca, E. A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.2.197 · Cited by 51
Self-citation
Therapeutic Targets in the ARF Tumor Suppressor Pathway
Saporita, A. J., Maggi, L. B., Apicelli, A. J., & Weber, J. D. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707781058869 · Cited by 49
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy
Shchors, K., Persson, A. I., Rostker, F., Tihan, T., Lyubynska, N., Li, N., Swigart, L. B., Berger, M. S., Hanahan, D., Weiss, W. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219142110 · Cited by 49
Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe, T., Katayama, Y., Yoshino, A., Komine, C., & Yokoyama, T. (2003) · PubMed · Cited by 46
Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme
Kamiryo, T., Tada, K., Shiraishi, S., Shinojima, N., Nakamura, H., Kochi, M., Kuratsu, J., Saya, H., & Ushio, Y. (2002) · Journal of neurosurgery · doi:10.3171/jns.2002.96.5.0815 · Cited by 46
Central nervous system
Adamson, D. C., Rasheed, B. A., McLendon, R. E., & Bigner, D. D. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0177 · Cited by 45
Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control
Hasan, M. K., Yaguchi, T., MINODA, Y., Hirano, T., Taira, K., Wadhwa, R., & Kaul, S. C. (2004) · Biochemical Journal · doi:10.1042/bj20040337 · Cited by 45
Astrocyte Differentiation States and Glioma Formation
Dai, C., & Holland, E. C. (2003) · The Cancer Journal · doi:10.1097/00130404-200303000-00002 · Cited by 45
Integrins and p53 pathways in glioblastoma resistance to temozolomide
Martin, S., Janoušková, H., & Dontenwill, M. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00157 · Cited by 43
Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver
Weihrauch, M., Markwarth, A., Lehnert, G., Wittekind, C., Wrbitzky, R., & Tannapfel, A. (2002) · Human Pathology · doi:10.1053/hupa.2002.126880 · Cited by 44
Molecular biology of gliomas
Lassman, A. B. (2004) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-004-0043-3 · Cited by 44
Genetic analysis of a multifocal glioblastoma multiforme: A suitable tool to gain new aspects in glioma development
Krex, D., Mohr, B., Appelt, H., Schackert, H. K., & Schackert, G. (2003) · Neurosurgery · doi:10.1227/01.neu.0000093426.29236.86 · Cited by 42
Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6
Merkel, C. A., Soares, R. B. D. S., de Carvalho, A. C. V., Zanatta, D. B., Bajgelman, M. C., Fratini, P., Costanzi-Strauss, E., & Strauss, B. E. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-316 · Cited by 43
Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma
Bradley, G., Irish, J., MacMillan, C., Mancer, K., Witterick, I., Hartwick, W. J., Gullane, P. J., Kamel‐Reid, S., & Benchimol, S. (2001) · Oncogene · doi:10.1038/sj.onc.1204131 · Cited by 41
Applications of mouse glioma models in preclinical trials
Hu, X., & Holland, E. C. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.08.023 · Cited by 40
Correlation of molecular genetic analysis of P53 MDM2 P16 PTEN and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma
Ushio, Y. (2003) · Frontiers in bioscience · doi:10.2741/865 · Cited by 41
PTEN: A potential prognostic marker in virus-induced hepatocellular carcinoma
Khalid, A., Hussain, T., Manzoor, S., Saalim, M., & Khaliq, S. (2017) · Tumor Biology · doi:10.1177/1010428317705754 · Cited by 39
Oncolytic viruses for the therapy of brain tumors and other solid malignancies a review
Chiocca, E. A. (2003) · Frontiers in bioscience · doi:10.2741/976 · Cited by 38
INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck
Weber, A., Bellmann, U., Bootz, F., Wittekind, C., & Tannapfel, A. (2002) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-002-0637-6 · Cited by 37
Genetic and Epigenetic Alterations of 9p21 Gene Products in Benign and Malignant Tumors of the Head and Neck
Weber, A., Wittekind, C., & Tannapfel, A. (2003) · Pathology - Research and Practice · doi:10.1078/0344-0338-00435 · Cited by 37
Heme Oxygenase-1 in Central Nervous System Malignancies
Sferrazzo, G., Rosa, M. D., Barone, E., Volti, G. L., Musso, N., Tibullo, D., & Barbagallo, I. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051562 · Cited by 36
p15 promoter methylation - A novel prognostic marker in glioblastoma patients
Urbschat (2009) · International Journal of Oncology · doi:10.3892/ijo_00000305 · Cited by 36
Gliomas: advances in molecular analysis and characterization
Boudreau, C. R., Yang, I., & Liau, L. M. (2005) · Surgical Neurology · doi:10.1016/j.surneu.2005.03.033 · Cited by 34
Genetically engineered mouse models of astrocytoma: GEMs in the rough?
Reilly, K. M., & Jacks, T. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0375 · Cited by 32
Prognostic Value of Mdm2, p53 and p16 in Patients with Astrocytomas
Ranuncolo, S. M., Varela, M. S., Morandi, A., Lastiri, J. M., Christiansen, S. B., Joffé, E. B. D. K., Pallotta, M. G., & Puricelli, L. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000027741.19213.99 · Cited by 32
The future role of personalized medicine in the treatment of glioblastoma multiforme
Adamson, C. (2010) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s6852 · Cited by 32
p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases
Korshunov, A., Голанов, А. В., & Timirgaz, V. (2001) · Acta Neuropathologica · doi:10.1007/s004010100379 · Cited by 31
Glioma models
Dai, C., & Holland, E. C. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00027-0 · Cited by 31
A Major Functional Difference between the Mouse and Human ARF Tumor Suppressor Proteins
Wadhwa, R., Sugihara, T., Hasan, M. K., Taira, K., Reddel, R. R., & Kaul, S. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203222200 · Cited by 31
Alterations of p53, BCL‐2, and hMSH2 protein expression in the normal brain tissues, gliosis, and gliomas
Hussein, M. R., Ghorori, R. M. H. E., & El-Rahman, Y. G. A. (2006) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2006.00482.x · Cited by 28
Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells—Relevance for Understanding (Germ Cell) Tumorigenesis
Timmerman, D. M., Remmers, T. L., Hillenius, S., & Looijenga, L. H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105377 · Cited by 26
The Failure in the Stabilization of Glioblastoma-Derived Cell Lines: Spontaneous In Vitro Senescence as the Main Culprit
Stoczyńska-Fidelus, E., Piaskowski, S., Bieńkowski, M., Banaszczyk, M., Hułas-Bigoszewska, K., Winiecka-Klimek, M., Radomiak-Załuska, A., Och, W., Borowiec, M., Zięba, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087136 · Cited by 27
MDM2 mRNA Expression in the p53 Pathway May Predict the Potential of Invasion and Liver Metastasis in Colorectal Cancer
Kondo, I., Iida, S., Takagi, Y., & Sugihara, K. (2008) · Diseases of the Colon & Rectum · doi:10.1007/s10350-008-9382-5 · Cited by 27
Brain tumors: molecular biology and targeted therapies
Hegi, M. E., Murat, A., Lambiv, W. L., & Stupp, R. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl259 · Cited by 27
Self-citation
Perturbations of the Ink4a/Arf gene locus in aflatoxin B1-induced mouse lung tumors
Tam, A. S. M. (2003) · Carcinogenesis · doi:10.1093/carcin/24.1.121 · Cited by 27
Loss of p19Arf Facilitates the Angiogenic Switch and Tumor Initiation in a Multi-Stage Cancer Model via p53-Dependent and Independent Mechanisms
Ulanet, D., & Hanahan, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012454 · Cited by 26
E2F activity is essential for survival of Myc-overexpressing human cancer cells
Santoni‐Rugiu, E., Duro, D., Farkas, T., Mathiasen, I. S., Jäättelä, M., Bártek, J., & Lukas, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205828 · Cited by 24
Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets
Ghimenti, C., Fiano, V., Chiadò-Piat, L., Chiò, A., Cavalla, P., & Schiffer, D. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1022127302008 · Cited by 21
Promoter hypermethylation and quantitative expression analysis of CDKN2A (p14ARF and p16INK4a) gene in esophageal squamous cell carcinoma.
Ito, S., Ohga, T., Saeki, H., Watanabe, M., Kakeji, Y., Morita, M., Yamada, T., & Maehara, Y. (2007) · PubMed · Cited by 21
Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme
Ramaiah, M. J., Adusumilli, K., Chamarthy, S., & Angirekula, H. S. R. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01234-2 · Cited by 23
Growth suppression by a p14ARF exon 1β adenovirus in human tumor cell lines of varying p53 and Rb status
Saadatmandi, N., Tyler, T., Huang, Y., Haghighi, A. P., Frost, G., Borgström, P., & Gjerset, R. A. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700505 · Cited by 20
Silatecan DB-67 is a novel DNA topoisomerase I–targeted radiation sensitizer
Chen, A. Y., Shih, S., Garriques, L. N., Rothenberg, M. L., Hsiao, M., & Curran, D. P. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.317.4.2 · Cited by 19
INK4a-ARF alterations in liver cell adenoma
Tannapfel, A., Busse, C., Geiβler, F., Witzigmann, H., Hauss, J., & Wittekind, C. (2002) · Gut · doi:10.1136/gut.51.2.253 · Cited by 19
Molecular genetic analysis of deep-seated glioblastomas
Hayashi, Y., Yamashita, J., & Watanabe, T. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2003.12.010 · Cited by 18
Molecular genetic and proteomic analysis of synchronous malignant gliomas
Zhuang, Z., Lee, Y.-S., Zeng, W., Furuta, M., Vályi-Nagy, T., Johnson, M. D., Vnencak-Jones, C. L., Woltjer, R. L., & Weil, R. J. (2004) · Neurology · doi:10.1212/wnl.62.12.2316 · Cited by 17
Genomic destabilization and its associated mutagenesis increase with senescence‐associated phenotype expression
Yoshioka, K., & Matsuno, Y. (2020) · Cancer Science · doi:10.1111/cas.14746 · Cited by 15
Towards MIB-1 and p53 detection in glioma magnetic resonance image: a novel computational image analysis method
Liu, C., Zhang, H., Pan, Y., Huang, F., & Xia, S. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/24/8393 · Cited by 15
Wip1 over‐expression correlated with TP53/p14ARF pathway disruption in human astrocytomas
Wang, P., Rao, J., Yang, H., Zhao, H., & Yang, L. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.22004 · Cited by 14
Evaluation of genetic alterations in cancer-related genes in lung and brain tumors from B6C3F1 mice exposed to 1,3-butadiene or chloroprene
Ton, T.-V. T., Hong, H. L., Devereux, T. R., Melnick, R. L., Sills, R. C., & Kim, Y. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.04.015 · Cited by 13
Delivery systems and molecular targets of mechanism-based therapies for GBM
Phuphanich, S., Brat, D. J., & Olson, J. J. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.4.649 · Cited by 12
Wild type p53-dependent transcriptional upregulation of cathepsin L expression is mediated by C/EBPα in human glioblastoma cells
Katara, R., Mir, R. A., Shukla, A. A., Tiwari, A., Singh, N., & Chauhan, S. S. (2010) · Biological Chemistry · doi:10.1515/bc.2010.103 · Cited by 12
KUB3 amplification and overexpression in human gliomas
Fischer, U., Hemmer, D., Heckel, D., Michel, A., Feiden, W., Steudel, W.-I., Hulsebos, T. J. M., & Meese, E. U. (2001) · Glia · doi:10.1002/glia.1090 · Cited by 12
Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant
Klein, M. A., Rüedi, D., Nozaki, M., Dell, E. W., Diserens, A., Seelentag, W. K. F., Janzer, R. C., Aguzzi, A., & Hegi, M. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203941 · Cited by 11
Self-citation
Genetic Alterations in Brain Tumors Following 1,3-Butadiene Exposure in B6C3F1 Mice
Kim, Y., Hong, H. L., Lachat, Y., Clayton, N. P., Devereux, T. R., Melnick, R. L., Hegi, M. E., & Sills, R. C. (2005) · Toxicologic Pathology · doi:10.1080/01926230590922848 · Cited by 11
Self-citation

Authors: Fulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M. E., Janzer, R. C., Merlo, A., & Van Meir, E. G.
Affiliations: Centre Hospitalier Universitaire Vaudois (CH)
University Hospital of Basel (CH)
ORCID: Fulci, Giulia
Hausmann, Oliver
Hegi, Monika E
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2000-07-28
Volume: 19
Issue: 33
Pages: 3816-3822
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1203700
OpenAlex: W2069294039
Cited by: 146
References: 41
Citations by year: 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 7 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 2 · 2013: 4 · 2012: 7
FWCI: 7.04
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: glioblastoma, TP53 mutation, INK4a/ARF locus, tumor suppressor, MDM2 overexpression, EGFR amplification, PTEN mutation, CDKN2A, loss of heterozygosity, p53 pathway
MeSH terms: Animals, Carrier Proteins, Glioblastoma, Humans, Nuclear Proteins, Phosphoric Monoester Hydrolases, Proteins, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Tumor Suppressor Protein p53, Mutagenesis, Gene Deletion, Cyclin-Dependent Kinase Inhibitor p16, Tumor Suppressor Proteins, Tumor Suppressor Protein p14ARF, PTEN Phosphohydrolase, Mice, Proto-Oncogene Proteins c-mdm2, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks